Oct 19, 2022Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight SessionRIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...
Oct 13, 2022Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of CancerYmmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for...
